HK1214633A1 - 癌症的分子診斷測試 - Google Patents
癌症的分子診斷測試Info
- Publication number
- HK1214633A1 HK1214633A1 HK16102633.1A HK16102633A HK1214633A1 HK 1214633 A1 HK1214633 A1 HK 1214633A1 HK 16102633 A HK16102633 A HK 16102633A HK 1214633 A1 HK1214633 A1 HK 1214633A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- diagnostic test
- molecular diagnostic
- molecular
- test
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Data Mining & Analysis (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732761P | 2012-12-03 | 2012-12-03 | |
| PCT/GB2013/053202 WO2014087156A1 (en) | 2012-12-03 | 2013-12-03 | Molecular diagnostic test for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214633A1 true HK1214633A1 (zh) | 2016-07-29 |
Family
ID=49780086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102633.1A HK1214633A1 (zh) | 2012-12-03 | 2016-03-08 | 癌症的分子診斷測試 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11091809B2 (zh) |
| EP (1) | EP2925885B1 (zh) |
| JP (1) | JP2015536667A (zh) |
| KR (1) | KR20150090246A (zh) |
| CN (1) | CN105102631A (zh) |
| AU (1) | AU2013353839A1 (zh) |
| CA (1) | CA2893033A1 (zh) |
| HK (1) | HK1214633A1 (zh) |
| IL (1) | IL239196A0 (zh) |
| MX (1) | MX2015006955A (zh) |
| SG (1) | SG11201504023SA (zh) |
| WO (1) | WO2014087156A1 (zh) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691257A1 (ru) | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
| JP2015536667A (ja) | 2012-12-03 | 2015-12-24 | アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ | 癌のための分子診断検査 |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| JP2017523776A (ja) * | 2014-07-14 | 2017-08-24 | ジェネンテック， インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
| CN104212440B (zh) * | 2014-09-03 | 2016-03-30 | 无锡艾德美特生物科技有限公司 | 一类喹唑啉类荧光探针及其制备和应用 |
| JP2018508183A (ja) * | 2014-12-23 | 2018-03-29 | ジェネンテック， インコーポレイテッド | 化学療法耐性癌を治療及び診断する組成物及び方法 |
| WO2017129537A1 (en) * | 2016-01-25 | 2017-08-03 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
| WO2017181079A2 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| JP7359547B2 (ja) * | 2016-05-17 | 2023-10-11 | ジェネンテック， インコーポレイテッド | 免疫療法における診断及び使用のための間質遺伝子シグネチャー |
| US11415584B2 (en) | 2016-12-28 | 2022-08-16 | Japanese Foundation For Cancer Research | Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug |
| ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| WO2018231771A1 (en) * | 2017-06-13 | 2018-12-20 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| US10636512B2 (en) * | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| EP3652663A4 (en) * | 2017-07-14 | 2021-04-21 | Cofactor Genomics, Inc. | IMMUNO-ONCOLOGICAL APPLICATIONS IMPLEMENTING NEXT GENERATION SEQUENCING |
| CN107621545B (zh) * | 2017-07-26 | 2019-10-11 | 东南大学 | Bicc1蛋白对精神疾病诊断的新用途 |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
| US20200294622A1 (en) * | 2017-12-04 | 2020-09-17 | Nantomics, Llc | Subtyping of TNBC And Methods |
| CN108524937B (zh) * | 2018-05-11 | 2020-05-05 | 中南大学湘雅三医院 | Mrvi1-as1作为靶位点在制备治疗鼻咽癌紫杉醇化疗增敏药物中的应用 |
| WO2020047204A1 (en) * | 2018-08-31 | 2020-03-05 | Seno Medical Instruments, Inc. | Methods and systems to determine cancer molecular subtypes based on ultrasound and-or optoacoustic ( oa/us) features |
| CN109585011A (zh) * | 2018-10-26 | 2019-04-05 | 朱海燕 | 胸痛患者的病症诊断方法及机器可读存储介质 |
| CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
| WO2021034091A1 (ko) * | 2019-08-19 | 2021-02-25 | 재단법인 아산사회복지재단 | 교모세포종의 진단 방법 |
| CN111105843B (zh) * | 2019-12-31 | 2023-07-21 | 杭州纽安津生物科技有限公司 | 一种hlai型分子与多肽的亲和力预测方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN112266961B (zh) * | 2020-10-29 | 2023-05-12 | 中山大学附属第六医院 | Tsg-6基因在预测结直肠癌转移及预后方面的应用 |
| CN112592397B (zh) * | 2020-12-31 | 2022-08-30 | 上海市胸科医院 | Ccdc80来源的多肽及其用途 |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| KR20220141216A (ko) * | 2021-04-12 | 2022-10-19 | 연세대학교 산학협력단 | 유방암 진단을 위한 신규 바이오마커 |
| WO2022241264A2 (en) * | 2021-05-13 | 2022-11-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis |
| CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
| CN116519954B (zh) * | 2023-06-28 | 2023-10-27 | 杭州广科安德生物科技有限公司 | 一种结直肠癌检测模型构建方法、***及生物标志物 |
| CN117089621A (zh) * | 2023-09-28 | 2023-11-21 | 上海爱谱蒂康生物科技有限公司 | 生物标志物组合及其在预测结直肠癌疗效中的应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| WO2004005883A2 (en) | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| US20030215424A1 (en) | 2002-05-15 | 2003-11-20 | Seul Kyung Hwan | Method of modulating angiogenesis |
| RS20150135A1 (en) | 2003-05-30 | 2015-08-31 | Genentech Inc. | TREATMENT WITH ANTI-VEGF ANTIBODIES |
| US7659062B2 (en) | 2003-06-03 | 2010-02-09 | The Board of Trustee of the University of Arkansas System | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| WO2005066371A2 (en) | 2003-12-31 | 2005-07-21 | The Penn State Research Foundation | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| ES2550614T3 (es) | 2004-04-09 | 2015-11-11 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| EP1743031A4 (en) * | 2004-04-26 | 2008-05-28 | Childrens Medical Center | BLOOD PLATE BIOMARKERS FOR THE DETECTION OF ILLNESSES |
| RU2006144122A (ru) | 2004-05-14 | 2008-06-20 | Лудуиг Инститьют Фор Кэнсе Рисеч (Us) | Идентификация и характеризация субпопуляции глиобластом, чувствительных к лечению иматинибом |
| AU2005263972A1 (en) | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
| US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| ATE477495T1 (de) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| US20080305962A1 (en) | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
| ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP1963862A4 (en) | 2005-12-05 | 2010-03-03 | Merck & Co Inc | METHODS FOR PREDICTING REACTION TO TREATMENT FROM EXPRESSION PROFILES OF PROTEIN AND TRANSCRIPTIONAL BIOMARKERS |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| KR20080094803A (ko) | 2006-01-27 | 2008-10-24 | 트리패스 이미징, 인코포레이티드 | 난소암의 발병 가능성이 높은 환자를 확인하는 방법 및 그의 조성물 |
| US20090275633A1 (en) | 2006-04-13 | 2009-11-05 | Oncomethylome Sciences Sa | Novel Tumour Suppressor |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CA2662508A1 (en) | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| EP2201142A1 (en) | 2007-08-13 | 2010-06-30 | Almac Diagnostics Limited | A 3' -based sequencing approach for microarray manufacture |
| US20090092603A1 (en) | 2007-09-25 | 2009-04-09 | Bamdad Cynthia C | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| BRPI0817158A2 (pt) | 2007-11-09 | 2015-04-14 | Genentech Inc | "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos" |
| CA2707900A1 (en) | 2007-12-07 | 2009-06-18 | Oregon Health & Science University | Methods to determine if a subject will respond to a bcr-abl inhibitor |
| AU2009209251B8 (en) * | 2008-01-28 | 2015-03-26 | Medimmune Limited | Stabilized Angiopoietin-2 antibodies and uses thereof |
| US8114593B2 (en) | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
| CA2726426A1 (en) | 2008-06-04 | 2009-12-10 | The Arizona Board Of Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
| CA2726811C (en) | 2008-06-06 | 2019-11-26 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large b cell lymphoma |
| EP2318543A2 (en) | 2008-07-16 | 2011-05-11 | Dana-Farber Cancer Institute Inc. | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| EA020764B1 (ru) * | 2008-12-23 | 2015-01-30 | Мерк Патент Гмбх | Биомаркеры для ингибиторов с антиангиогенной активностью |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| SG175832A1 (en) * | 2009-05-01 | 2011-12-29 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| US7615353B1 (en) | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| ES2530732T3 (es) * | 2009-09-17 | 2015-03-05 | Hoffmann La Roche | Procedimientos de diagnóstico para el cáncer de pulmón |
| CA2811015A1 (en) * | 2010-09-15 | 2012-03-22 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| US20130261018A1 (en) * | 2010-10-20 | 2013-10-03 | University Of Tennessee Research Foundation | Interferon gene signature and methods of use thereof |
| WO2012052757A1 (en) | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| EP2659005A4 (en) | 2010-12-28 | 2016-08-24 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| EA201691257A1 (ru) * | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
| SG11201403927XA (en) | 2012-01-13 | 2014-08-28 | Genentech Inc | Biological markers for identifying patients for treatment with vegf antagonists |
| EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| JP2015536667A (ja) | 2012-12-03 | 2015-12-24 | アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ | 癌のための分子診断検査 |
-
2013
- 2013-12-03 JP JP2015544542A patent/JP2015536667A/ja active Pending
- 2013-12-03 CA CA2893033A patent/CA2893033A1/en not_active Abandoned
- 2013-12-03 EP EP13808178.1A patent/EP2925885B1/en active Active
- 2013-12-03 MX MX2015006955A patent/MX2015006955A/es unknown
- 2013-12-03 SG SG11201504023SA patent/SG11201504023SA/en unknown
- 2013-12-03 KR KR1020157017703A patent/KR20150090246A/ko not_active Application Discontinuation
- 2013-12-03 WO PCT/GB2013/053202 patent/WO2014087156A1/en active Application Filing
- 2013-12-03 US US14/649,421 patent/US11091809B2/en active Active
- 2013-12-03 CN CN201380071098.3A patent/CN105102631A/zh active Pending
- 2013-12-03 AU AU2013353839A patent/AU2013353839A1/en not_active Abandoned
-
2015
- 2015-06-03 IL IL239196A patent/IL239196A0/en unknown
-
2016
- 2016-03-08 HK HK16102633.1A patent/HK1214633A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11091809B2 (en) | 2021-08-17 |
| WO2014087156A1 (en) | 2014-06-12 |
| IL239196A0 (en) | 2015-07-30 |
| SG11201504023SA (en) | 2015-06-29 |
| CN105102631A (zh) | 2015-11-25 |
| US20160002732A1 (en) | 2016-01-07 |
| CA2893033A1 (en) | 2014-06-12 |
| EP2925885A1 (en) | 2015-10-07 |
| AU2013353839A1 (en) | 2015-06-18 |
| MX2015006955A (es) | 2016-01-25 |
| KR20150090246A (ko) | 2015-08-05 |
| EP2925885B1 (en) | 2020-02-05 |
| JP2015536667A (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214633A1 (zh) | 癌症的分子診斷測試 | |
| ZA201508689B (en) | Molecular diagnostic test for cancer | |
| IL229681A0 (en) | A molecular diagnostic test for cancer | |
| HK1245888A1 (zh) | 對癌症的代理功能性診斷測試 | |
| IL244472A0 (en) | Molecular diagnostic test for lung cancer | |
| HRP20181576T1 (hr) | Blok za dijagnosticiranje transakcije | |
| EP2699144A4 (en) | STUDY INSTRUMENT | |
| SG2013079553A (en) | Rf testing system | |
| IL244471A0 (en) | Molecular diagnostic test for esophageal cancer | |
| GB2518081B (en) | Providing an ID-verified blood test | |
| GB2507283B (en) | Probe | |
| EP2524702A4 (en) | DIAGNOSTIC TO CANCER | |
| EP2870499A4 (en) | DIAGNOSTIC DEVICE | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| EP2832302A4 (en) | PROBE | |
| SG11201502499UA (en) | Cancer diagnosis device | |
| EP2742358A4 (en) | METHOD FOR THE DIAGNOSIS OF CANCER | |
| HK1200723A1 (zh) | 藥學診斷 | |
| EP2826412A4 (en) | PROBE | |
| EP2870998A4 (en) | TEST TUBE | |
| GB2505193B (en) | Probe | |
| AP2013008332A0 (en) | Diagnostic probe | |
| TWI560452B (en) | Probe card for circuit-testing | |
| HU4255U (en) | Diagnostic device for sole-pressure distribution | |
| TWI560451B (en) | Probe card for circuit-testing |